Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve
Lillian M Toomey1, Carole A Bartlett1, Maimuna Majimbi2
1Experimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, 35 Stirling Hwy, Perth, WA, 6009, Australia.
Abstract:
Following neurotrauma, secondary degeneration of neurons and glia adjacent to the injury leads to further functional loss. A combination of ion channel inhibitors (lomerizine + oxATP + YM872) has been shown to be effective at limiting structural and functional loss due to secondary degeneration. Here we assess efficacy of the combination where oxATP is replaced with Brilliant Blue G (BBG), a more clinically applicable P2X7 receptor inhibitor. Partial optic nerve transection was used to model secondary degeneration in adult female rats. Animals were treated with combinations of lomerizine + YM872 + oxATP or lomerizine + YM872 + BBG, delivered via osmotic mini-pump directly to the injury site. Outcomes assessed were Iba1 + and ED1 + microglia and macrophages, oligodendroglial cell numbers, node/paranode structure and visual function using the optokinetic nystagmus test. The lomerizine + BBG + YM872 combination was at least as effective at the tested concentrations as the lomerizine + oxATP + YM872 combination at preserving node/paranode structure and visual function when delivered locally. However, neither ion channel inhibitor combination significantly improved microglial/macrophage nor oligodendroglial numbers compared to vehicle-treated controls. In conclusion, a locally delivered combination of ion channel inhibitors incorporating lomerizine + BBG + YM872 is at least as effective at limiting secondary degeneration following partial injury to the optic nerve as the combination incorporating oxATP.
Insights
A new drug combination, lomerizine plus Brilliant Blue G (BBG) and YM872, effectively limits secondary degeneration after optic nerve injury. This treatment preserves nerve structure and visual function, offering a promising alternative for neurotrauma recovery.
Area of Science:
- Neuroscience
- Ophthalmology
- Pharmacology
Background:
- Secondary degeneration following neurotrauma exacerbates neuronal and glial loss, leading to functional deficits.
- Previous studies indicated that a combination of ion channel inhibitors (lomerizine + oxATP + YM872) could mitigate secondary degeneration.
- Brilliant Blue G (BBG) is a more clinically applicable P2X7 receptor inhibitor than oxATP.
Purpose of the Study:
- To evaluate the efficacy of a novel ion channel inhibitor combination (lomerizine + BBG + YM872) in limiting secondary degeneration after optic nerve injury.
- To compare the effectiveness of BBG-containing combination with the oxATP-containing combination in a rat model.
Main Methods:
- Partial optic nerve transection was performed in adult female rats to induce secondary degeneration.
- Animals received local treatment via osmotic mini-pump with either lomerizine + oxATP + YM872 or lomerizine + BBG + YM872.
- Evaluated outcomes included microglial/macrophage counts (Iba1+, ED1+), oligodendroglial cell numbers, node/paranode structure, and visual function (optokinetic nystagmus test).
Main Results:
- The lomerizine + BBG + YM872 combination demonstrated comparable efficacy to the lomerizine + oxATP + YM872 combination in preserving node/paranode structure and visual function.
- Neither combination significantly improved microglial/macrophage or oligodendroglial cell counts compared to vehicle controls.
- Local delivery of the BBG-based ion channel inhibitor combination effectively limited secondary degeneration.
Conclusions:
- A locally delivered combination of lomerizine, BBG, and YM872 is as effective as the oxATP-containing combination in limiting secondary degeneration after partial optic nerve injury.
- This BBG-based combination shows promise for preserving structural integrity and visual function in neurotrauma models.
- Further research may be needed to enhance effects on glial cell populations.
Related Concept Videos
Ion Channels
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Mechanically-gated Ion Channels
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
G-Protein Gated Ion Channels
Sensory...


